Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of transdermal rotigotine in idiopathic restless legs syndrome
2005-002611-25Phase 3Completed
- Sponsor
- Schwarz Pharma
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rotigotine in restless legs syndrome (RLS), sponsored by Schwarz Pharma. Primary endpoint: Safety and tolerability (adverse events). Started Sep 2005; status: completed.
02
Drugs
rotigotine
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on 2005-002611-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002611-25.